Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by Houndtraderon Nov 03, 2015 4:17pm

196 Views

Post# 24255045

RE:RE:Partnership with Alimera Sciences

Thanks I've been told the Canadian fda approval seems to take forever, but I thought once it's been used in usa Europe and other countries, the process wouldn't take so long. Doesn't really matter what drug u use, they all have warnings before use.

Bullboard Posts

New Nintendo console possibly leaked by 3rd party at CES 2025